Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

par Samtani MN, Nuamah I, Gopal S, Remmerie B, Sliwa JK, Alphs L
Publié 2013

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

par Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D
Publié 2013

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

par Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Publié 2019

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

par Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Publié 2018

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

par Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Publié 2020

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

par Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Publié 2019

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study

par Zhang H, Li H, Liu Y, Wu C, Wu Q, Nuamah I, Shi J, Xie S, Wang G, Gopal S
Publié 2016

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase II...

par Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Publié 2017